VSTMVerastem, Inc.Signing up patients
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Low Grade Serous Ovarian Cancer
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +11.5
A key executive is leaving
Since Oct 14, 2026 · was worth 15, fading over time
Worry score12
Score over time
- Stage
- Phase 3
- Patients
- 270 (planned)
- Started
- Mar 18, 2024
- Main results expected
- Oct 15, 2028
- Fully finished
- Feb 9, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) per blinded independent central review (BICR)
Measured over: Up to 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 11.5, since 2026-10-14, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT06072781 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC